Several retrospective studies demonstrated that baseline serum alpha-fetoprotein (AFP) level and early on-treatment response of AFP were associated with therapeutic efficacy and prognosis for HCC patients treated with ICI-based regimens [12–14]. This evidence concerns the gene AFP and hepatocellular carcinoma.